Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Elanco Animal Health Incorporated

The Better Cat offers preventive cat food and supplements. The brand emphasizes the use of high-quality animal ingredients and aims to support various aspects of cat health.

The Better Cat

BEWITAL agri develops innovative specialty feed products suited to the needs of the farming and feed industry. The company focuses on animal health, growth, yield, and environmental protection.

BEWITAL agri GmbH & Co. KG

Elanco provides products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. This is a self-described leading provider of innovative solutions in animal health.

Metric
Company Name	Elanco Animal Health Incorporated	The Better Cat	BEWITAL agri GmbH & Co. KG
Symbol	ELAN
MSH ID	COM:ELANCO	COM:THEBETTERCAT	DE:BEWITAL-AGRI
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Consumer Goods	Consumer Goods
Industry	Drug Manufacturers - Specialty & Generic	Pet Food	Food & Beverage
Country	US	DE	DE
Stage
Employee Count	9.30K
Website	elanco.com	thebettercat.com	bewital-agri.de
LinkedIn			bewital-agri-gmbh-co-kg
Founders

Metric
Market Cap	6.56B
Enterprise Value
Monthly Web Traffic		17.71K	1.30K
Web Traffic Growth		0.14	-0.01
Valuation
Raised Capital

Metric
Revenue	4.42B
Revenue (LTM)
Revenue (NTM)
Gross Profit	2.49B
EBITDA	945M
Operating Income	326M
Net Income	-1.23B
EPS	-2.50
Diluted EPS	-2.50
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.56
Operating Profit Margin	0.06
EBITDA Margin	0.21
Net Profit Margin	-0.28
Return on Equity	-0.18
Return on Assets	-0.09
Return on Capital Employed	0.02

COM:ELANCO

Elanco

Last Close

13.40

22/11 21:00

Market Cap

6.56B

Beta: -

Volume Today

3.63M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-6.79
P/B Ratio	1.27
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.09
EV Multiple	4.97

Metric
Days Sales Outstanding	94.80
Days Payables Outstanding	57.99
Days Inventory Outstanding	327.95
Operating Cycle	411.41
Cash Conversion Cycle	360.38
Asset Turnover	0.33

Metric
Operating Cash Flow	271M
Free Cash Flow	117M
Cash Flow to Debt	0.10
Operating Cash Flow/Sales	0.12
Free Cash Flow Yield	-0.01

Metric
Cash & Equivalents	352M
Accounts Receivable	-40M
Inventory	1.74B
Goodwill	5.09B
Debt to Capitalization	0.49
Debt to Assets	0.41
Current Ratio	2.82
Quick Ratio	1.96

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01
R&D to Revenue	0.08
SG&A to Revenue